Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, first-in-human single-dose escalation study to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of OA-235i in subjects with nonalcoholic
steatohepatitis.
Phase:
Phase 1
Details
Lead Sponsor:
Oasis Pharmaceuticals, LLC
Collaborators:
Mayo Clinic National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)